Making Glioblastoma Treatments More Effective
Therapeutic targeting of the SWI/SNF chromatin remodeler to regulate GBM chemosensitivity
This research explores new ways to make current glioblastoma treatments work better by targeting specific pathways in cancer cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Health Sci Ctr NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project ID | NIH-11103213 on NIH RePORTER |
What this research studies
Glioblastoma (GBM) is a very aggressive brain cancer where tumor cells often become resistant to standard treatments. This project focuses on understanding and targeting a specific protein called BRG1, which helps glioblastoma stem cells survive and resist therapy. By using new medications that block BRG1, we hope to make these resistant cancer cells more vulnerable to existing chemotherapy. This approach could also potentially boost the body's own immune response against the tumor.
Who could benefit from this research
Good fit: This foundational research is for adult patients with glioblastoma, especially those whose tumors are resistant to standard chemotherapy.
Not a fit: Patients without glioblastoma or those whose tumors are already highly responsive to current treatments may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new treatment strategies that improve how well current glioblastoma therapies work, potentially extending patient lives.
How similar studies have performed: Previous findings from this team have identified BRG1's role in glioblastoma resistance and developed new inhibitors, suggesting a promising direction for this approach.
Where this research is happening
Memphis, United States
- University of Tennessee Health Sci Ctr — Memphis, United States (Active)
Researchers
- Principal investigator: Pfeffer, Lawrence Marc — University of Tennessee Health Sci Ctr
- Study coordinator: Pfeffer, Lawrence Marc
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.